Abstract: Surface-enhanced Raman spectroscopic (SERS) systems and methods for detecting and differentiating biomolecules of interest, such as human immunodeficiency virus (HIV), are provided.

Abstract: Surface-enhanced Raman spectroscopic (SERS) systems and methods for detecting biomolecules of interest, such as a bacterium or virus are provided.

Abstract: Aspects of the present disclosure relate to therapeutic RNAi compositions and methods of use thereof for treating and/or preventing disease, disorder, and/or conditions—associated with bovine respiratory syncytial virus (BRSV) infections in cattle.

Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.

Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.

Abstract: Compositions, systems and methods for the detection of analytes with labeled nanostructures are provided. In particular, compositions and systems including labeled nanostructures for detecting a biomolecule of interest, and methods of use thereof, are provided.

Abstract: Surface-enhanced Raman spectroscopic (SERS) systems including nanostructures and capable of detecting analytes, in particular biomolecules, of interest are provided. Methods of making the SERS systems and methods for detection of a biomolecule of interest, such as a virus or other infectious agent are also provided.

Abstract: The present invention provides methods for preventing or treating a disease in a subject which is caused by an inflammatory response to a disease or syndrome which is mediated by endogenous substance P. These methods comprise the administration to the subject of a pharmaceutically-effective amount of anti-substance P antibodies, or anti-substance P antibody fragments, such as F(ab)2 fragments, thereby inhibiting the activity of endogenous substance P in the subject. By inhibiting the activity of endogenous substance P in the subject, the levels of cytokines produced by T lymphocytes present in the subject are reduced, the signals which direct the inflammatory response to the infection become altered, and the amount of cytokine-induced inflammation becomes reduced. Respiratory syncytial virus is one example of an agent which causes an infection which often results in a disease caused by an inflammatory response to the infection mediated by endogenous substance P. Generally, from about 0.

Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.

Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.

Abstract: The present invention provides a composition comprising: 1) macroaggregated albumin, 2) a nucleic acid comprising a nucleotide sequence encoding an RSV protein, and 3) polyethylamine (PEI), wherein the MAA, PEI and nucleic acid form a complex. Also provided by the present invention is a method of preventing respiratory syncytial virus (RSV) infection in a subject comprising administering to the subject an amount of a composition of this invention.

Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.